Eric Topol Appointed to the AltheaDx Scientific Advisory Board

SAN DIEGO, CA--(Marketwire - May 14, 2009) -

Highlighted Links

http://www.altheadx.com

http://www.altheatech.com

AltheaDx, a world leader in the development of companion diagnostics and biopharma services, today announced the appointment of Dr. Eric Topol to their Scientific Advisory Board. Eric J. Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. He is Professor of Translational Genomics at The Scripps Research Institute, the Chief Academic Officer of Scripps Health, and a Senior Consultant cardiologist practitioner at Scripps Clinic. In 2009, he became the Gary and Mary West Chair of Innovative Medicine and co-founded the West Wireless Health Institute.

"We are very pleased to have Dr. Topol join our Scientific Advisory Board," said David Macdonald, CEO of AltheaDx. "Eric brings to our Board a wealth of knowledge in translational medicine that will support the AltheaDx strategy of bringing theranostics into clinical use. Dr. Topol will be a catalyst for our expanding pipeline of companion diagnostics and will allow us to develop exciting new alliances."

AltheaDx provides its customers with a full range of molecular biopharma services; from biomarker discovery, clinical studies, diagnostic translation, through to reporting clinical results.

Prior to joining Scripps, Dr. Topol served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, and founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack has led to discovery of key genes (MEF2A deletion, THSB-4 variant) and recognition by the American Heart Association top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro). He has over 1000 original peer reviewed publications, and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed). Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine in the past decade.

About AltheaDx

AltheaDx is bringing theranostics into clinical use. The goal of AltheaDx is to reduce the time and risk of therapeutic development and to provide high-value testing services. For additional information, please visit: www.altheadx.com.

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: biotech advisory companion diagnostic cardiovascular gene expression genotyping biomarker bio